Prot# D1690C00032: Dapagliflozin EFfect on symptoms and bIomarkers iN diabetEs patients with Heart Failure (DEFINE-HF)

Project: Research project

StatusActive
Effective start/end date2/27/172/27/20

Funding

  • Saint Luke's Hospital of Kansas City (Prot# D1690C00032)
  • AstraZeneca Pharmaceuticals LP (Prot# D1690C00032)